Date/Time: Wednesday, October 7, 2020 - 3:30 PM – 5:30 PM
Track: Special Interest Group
Log in to Add to My Schedule
With a growing number of FDA-approved therapies that reduce multiple sclerosis (MS) inflammatory activity, much active research in the field is focused on identifying means of promoting remyelination, neuroprotection, and neurorepair. This SIG will focus on animal data surrounding remyelination, outcome measures that may be useful for human trials of neuroprotection/repair agents, and provide an update on a promising candidate therapy for remyelination.
To describe remyelination in animal models of MS.
To describe imaging outcome measures for trials of remyelination, neuroprotection, or neurorepair in MS.
To describe a candidate remyelination therapy in MS.